Cognitive vitality.
Genetically validated.
“Restoring α-Klotho levels is a biologically rational and clinically urgent therapeutic strategy.”
Dena Dubal, MD, PhD · UCSF
Leading authority on α-Klotho research
Jocasta is driven by leading experts in cognitive health, including Dena Dubal, MD, Albert Agro, PhD, Ned David, PhD, and Michael Davidson, MD
Meet the people behind Jocasta →
Powering the potential oF Klotho
We all carry the gene for α-Klotho, a natural protein that protects the brain. Its levels drop with age and stress, raising the risk of memory loss and brain disease. People with the lowest α-Klotho levels—including those with mild cognitive impairment, Alzheimer's, Parkinson's-related dementia, or the APOE ε4 variant—face the greatest risk.
Nature offers proof it can be different: about 1 in 4 people are born with higher α-Klotho levels, and they tend to have sharper memory and lower disease risk—even with APOE ε4.
Our therapy is designed to help restore that same natural protection.
α-Klotho rapidly and durably enhances cognition
In a peer-reviewed study, aged rhesus macaques—whose cognitive aging closely mirrors humans in their 50s through 80s—received a single subcutaneous injection of α-Klotho.
Working memory improved significantly within 4 hours, with benefits persisting for up to 6 weeks after that single dose.
A Single Dose of α-Klotho Can Enhance Cognition in Non-Human Primates for up to 6 Weeks
Adapted from Castner et al., Nat. Aging 3, 931–937 (2023)
JN-0413
poised to take the next step
At Jocasta, we are focused on the therapeutical potential of Klothoto ultimately improving how we age. Klotho JN-04133, our proprietary synthetic subcutaneous formulation, is a first-in-class, best-in-class treatment.
We are enthusiastically awaiting human trials, estimated to begin in 2026, pending ongoing manufacturing.
Why Jocasta
For the millions living with mild cognitive impairment — and the families beside them — effective treatment has been out of reach for too long. We’re targeting the root cause of brain aging to change that.
Millions Waiting
Millions living with MCI deserve better treatment options
Nature’s Blueprint
A target confirmed by human genetics and natural biology
Exclusive IP
Jocasta holds exclusive rights to α-Klotho treatment in neurodegenerative diseases
Patient-Centered
Experts focused on brain and memory disease
IND Q4 2026
On track to enter clinical trials by Q1 2027
